259 related articles for article (PubMed ID: 1352553)
1. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist.
Mottola DM; Brewster WK; Cook LL; Nichols DE; Mailman RB
J Pharmacol Exp Ther; 1992 Jul; 262(1):383-93. PubMed ID: 1352553
[TBL] [Abstract][Full Text] [Related]
2. 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.
Ghosh D; Snyder SE; Watts VJ; Mailman RB; Nichols DE
J Med Chem; 1996 Jan; 39(2):549-55. PubMed ID: 8558526
[TBL] [Abstract][Full Text] [Related]
3. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
Hess EJ; Albers LJ; Le H; Creese I
J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
[TBL] [Abstract][Full Text] [Related]
4. Acute in vivo amphetamine produces a homologous desensitization of dopamine receptor-coupled adenylate cyclase activities and decreases agonist binding to the D1 site.
Roseboom PH; Gnegy ME
Mol Pharmacol; 1989 Jan; 35(1):139-47. PubMed ID: 2563306
[TBL] [Abstract][Full Text] [Related]
5. trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist.
Brewster WK; Nichols DE; Riggs RM; Mottola DM; Lovenberg TW; Lewis MH; Mailman RB
J Med Chem; 1990 Jun; 33(6):1756-64. PubMed ID: 1971308
[TBL] [Abstract][Full Text] [Related]
6. Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping.
Mottola DM; Laiter S; Watts VJ; Tropsha A; Wyrick SD; Nichols DE; Mailman RB
J Med Chem; 1996 Jan; 39(1):285-96. PubMed ID: 8568818
[TBL] [Abstract][Full Text] [Related]
7. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum.
Onali P; Olianas MC; Gessa GL
Mol Pharmacol; 1985 Aug; 28(2):138-45. PubMed ID: 2410769
[TBL] [Abstract][Full Text] [Related]
8. Multiple dopamine receptors mediate the discriminative stimulus effects of dihydrexidine in rats.
Gleason SD; Yin T; Little SP; Delapp N; Witkin JM
Behav Pharmacol; 2011 Sep; 22(5-6):531-9. PubMed ID: 21836463
[TBL] [Abstract][Full Text] [Related]
9. Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist.
Darney KJ; Lewis MH; Brewster WK; Nichols DE; Mailman RB
Neuropsychopharmacology; 1991 Nov; 5(3):187-95. PubMed ID: 1684499
[TBL] [Abstract][Full Text] [Related]
10. Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist.
Knoerzer TA; Nichols DE; Brewster WK; Watts VJ; Mottola D; Mailman RB
J Med Chem; 1994 Jul; 37(15):2453-60. PubMed ID: 7914538
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of a dopamine D1 receptor enhances inositol phosphates formation in rat brain.
Undie AS; Friedman E
J Pharmacol Exp Ther; 1990 Jun; 253(3):987-92. PubMed ID: 1972756
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.
Enjalbert A; Bockaert J
Mol Pharmacol; 1983 May; 23(3):576-84. PubMed ID: 6306429
[TBL] [Abstract][Full Text] [Related]
13. Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain.
Levant B; Grigoriadis DE; DeSouza EB
J Pharmacol Exp Ther; 1992 Sep; 262(3):929-35. PubMed ID: 1356154
[TBL] [Abstract][Full Text] [Related]
14. Spare receptors and intrinsic activity: studies with D1 dopamine receptor agonists.
Watts VJ; Lawler CP; Gonzales AJ; Zhou QY; Civelli O; Nichols DE; Mailman RB
Synapse; 1995 Oct; 21(2):177-87. PubMed ID: 8584979
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of the receptor mediating electrophysiological responses to dopamine in the rat medial prefrontal cortex: a microiontophoretic study.
Sesack SR; Bunney BS
J Pharmacol Exp Ther; 1989 Mar; 248(3):1323-33. PubMed ID: 2564893
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors.
Knoerzer TA; Watts VJ; Nichols DE; Mailman RB
J Med Chem; 1995 Aug; 38(16):3062-70. PubMed ID: 7636869
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
[TBL] [Abstract][Full Text] [Related]
18. Partial and full dopamine D1 agonists produce comparable increases in ventral pallidal neuronal activity: contribution of endogenous dopamine.
Heidenreich BA; Mailman RB; Nichols DE; Napier TC
J Pharmacol Exp Ther; 1995 Apr; 273(1):516-25. PubMed ID: 7714807
[TBL] [Abstract][Full Text] [Related]
19. Agonist-induced desensitization of D2 dopamine receptors in human Y-79 retinoblastoma cells.
Barton AC; Black LE; Sibley DR
Mol Pharmacol; 1991 May; 39(5):650-8. PubMed ID: 1674585
[TBL] [Abstract][Full Text] [Related]
20. trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist.
Cueva JP; Giorgioni G; Grubbs RA; Chemel BR; Watts VJ; Nichols DE
J Med Chem; 2006 Nov; 49(23):6848-57. PubMed ID: 17154515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
